<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814108</url>
  </required_header>
  <id_info>
    <org_study_id>ZN-c3-004</org_study_id>
    <nct_id>NCT04814108</nct_id>
  </id_info>
  <brief_title>A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma</brief_title>
  <official_title>A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>K-Group Beta</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>K-Group Beta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to evaluate the clinical activity, safety, pharmacokinetics (PK), and&#xD;
      related biomarkers of ZN-c3 in adult women with recurrent or persistent uterine serous&#xD;
      carcinoma (USC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 open-label, multicenter study to evaluate the clinical activity, safety,&#xD;
      pharmacokinetics (PK), and related biomarkers of ZN-c3 in adult women with recurrent or&#xD;
      persistent uterine serous carcinoma (USC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the antitumor activity of ZN-c3 based on the objective response rate (ORR).</measure>
    <time_frame>2 years</time_frame>
    <description>Objective response rate (ORR) as defined by the revised Response Evaluation Criteria in Solid Tumors RECIST Guideline version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the antitumor clinical activity based on Duration of Response (DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of Response (DOR) as defined by the revised RECIST Guideline version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the antitumor clinical activity based on Progression-Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Progression- free survival (PFS) as defined by the revised RECIST Guideline version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety and tolerability of ZN-c3</measure>
    <time_frame>2 years</time_frame>
    <description>Frequency and severity of AEs, including laboratory abnormalities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Uterine Serous Carcinoma</condition>
  <arm_group>
    <arm_group_label>ZN-c3 Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZN-c3</intervention_name>
    <description>ZN-c3 is an investigational drug.</description>
    <arm_group_label>ZN-c3 Single Agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females age ≥18 years of age at the time of informed consent.&#xD;
&#xD;
          -  Recurrent or persistent USC.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.&#xD;
&#xD;
          -  Measurable disease, defined as at least one lesion that can be accurately measured per&#xD;
             revised Response Evaluation Criteria in Solid Tumors RECIST Guideline version 1.1&#xD;
             criteria.&#xD;
&#xD;
          -  Adequate hematologic and organ function.&#xD;
&#xD;
          -  Females of childbearing potential must agree to use an effective method of&#xD;
             contraception per institutional standard prior to the first dose and for 90 days after&#xD;
             the last dose of ZN c3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a cell cycle checkpoint inhibitor.&#xD;
&#xD;
          -  Prior therapy with ZN-c3 or any other WEE1 inhibitor.&#xD;
&#xD;
          -  A serious illness or medical condition(s).&#xD;
&#xD;
          -  Unresolved toxicity of Grade &gt; 1 attributed to any prior therapies (excluding ≤Grade 2&#xD;
             neuropathy, alopecia, or skin pigmentation).&#xD;
&#xD;
          -  Pregnant or lactating females (including the cessation of lactation) or females of&#xD;
             childbearing potential who have a positive serum pregnancy test within 28 days prior&#xD;
             to C1D1.&#xD;
&#xD;
          -  Subjects with active (uncontrolled, metastatic) second malignancies or requiring&#xD;
             therapy.&#xD;
&#xD;
          -  12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of&#xD;
             &gt; 480 ms at screening, except for subjects with atrioventricular pacemakers or other&#xD;
             conditions (e.g., right bundle branch block) that render the QT measurement invalid.&#xD;
&#xD;
          -  History or current evidence of congenital or family history of long QT syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Project Director</last_name>
    <phone>(858) 263-4333</phone>
    <email>info@zenopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 0116</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0114</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0113</name>
      <address>
        <city>Sterling</city>
        <state>Michigan</state>
        <zip>48659</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0117</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0130</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2703</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2706</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2704</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 3401</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 3S1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1406</name>
      <address>
        <city>Rustavi</city>
        <state>Kvemo Kartli</state>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1407</name>
      <address>
        <city>Batumi</city>
        <state>Republic Of Adjara</state>
        <zip>6000</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Georgia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

